Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05135286 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
A Phase 3 study of Presbyopia, sponsored by Visus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 629
- Enrollment target
- 20
- Study locations
NCT05135286 is a Phase 3 study of Presbyopia that has completed, run by Visus Therapeutics. The registered enrollment target is 629 participants, above the 254-participant average among 38 other Presbyopia trials with a reported enrollment target (148% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT05135286, a Phase 3 study of Presbyopia, has completed, sponsored by Visus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 629 participants
- Enrollment target
- 20
- Study locations
Study Summary
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG BRIMOCHOL™ PF
- DRUG Carbachol PF
Study Locations (20)
California
- Visus Therapeutics Investigative Site - Glendale
- Visus Therapeutics Investigative Site - Inglewood
- Visus Therapeutics Investigative Site - Irvine
- Visus Therapeutics Investigative Site - Mission Hills
- Visus Therapeutics Investigative Site - Newport Beach
- Visus Therapeutics Investigative Site - Pasadena
- Visus Therapeutics Investigative Site - Santa Barbara
Florida
- Visus Therapeutics Investigative Site - Crystal River
- Visus Therapeutics Investigative Site - Delray Beach
- Visus Therapeutics Investigative Site - Fort Lauderdale
- Visus Therapeutics Investigative Site - Jacksonville
- Visus Therapeutics Investigative Site - Largo
- Visus Therapeutics Investigative Site - Mt. Dora
Arizona
- Visus Therapeutics Investigative Site - Chandler
- Visus Therapeutics Investigative Site - Phoenix
- Visus Therapeutics Investigative Site - Sun City
Colorado
- Visus Therapeutics Investigative Site - Littleton
Connecticut
- Visus Therapeutics Investigative Site - Danbury
Illinois
- Visus Therapeutics Investigative Site - Lake Villa
Indiana
- Visus Therapeutics Investigative Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05135286
The ClinicalTrials.gov registry entry for NCT05135286 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 629 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 254-participant average among 38 other Presbyopia trials with a reported enrollment target (148% higher). The listed sponsor is Visus Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.
NCT05135286 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05135286 about?
NCT05135286 is a clinical study titled "Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia". Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
What is the current status of trial NCT05135286?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 629 participants. The study started on 2022-03-15. Estimated completion is 2025-03-13.
What conditions does trial NCT05135286 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT05135286?
The interventions under investigation include: Vehicle (DRUG), BRIMOCHOL™ PF (DRUG), Carbachol PF (DRUG).
Who is sponsoring clinical trial NCT05135286?
This trial is sponsored by Visus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05135286 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III Presbyopia Correction Using the VIS Opti-K™ System
RECRUITING · Phase 3
-
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
COMPLETED · Phase 3
-
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
COMPLETED · Phase 3
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.